MISSION & VISION
Addressing the roots of disease. Expanding treatment options.
Biozipcode, Inc. conducts research and development for diabetes and other hard-to-treat diseases, looking beyond symptom management to the cells and biological mechanisms that may sustain these conditions.
Our goal is to take research beyond scientific publications.
We work to develop discoveries made at universities and research institutions into reproducible technologies, protect them as intellectual property, and bring them into healthcare as diagnostics, therapeutics, and medical materials.
That is the mission of Biozipcode, Inc.
MISSION
Understanding disease at the cellular level,
and developing new treatments that address its roots.
In treating diabetes and many other chronic diseases, managing symptoms and slowing progression play vital roles in today’s healthcare.
But important questions remain: Why do some diseases persist for years? Why can the underlying condition remain after treatment? Why do complications affect multiple organs?
We move beyond clinical measures and symptoms by focusing on the cells that drive and sustain disease, opening new possibilities for diagnosis and treatment.
Through diabetes stem cell research and Biozipcode™ cell-targeting technology, we seek to understand and measure disease, identify its cellular targets, and develop treatments for them.
Together, these research efforts aim to create new options for people with hard-to-treat diseases.
Bringing research to patients
Turning basic research into new medicine
VISION
Making it routine to deliver the right treatment
to the right cells.
We envision a future in which care moves beyond treating everyone with the same diagnosis in the same way. By understanding each patient’s disease and its target cells, we can work toward delivering treatment suited to those cells.
Biozipcode™ aims to identify specific cells and tissues and selectively deliver the drugs or therapeutic molecules they need.
If established, this technology could improve treatment effects, limit off-target activity, and make it possible to redesign drugs and therapies that have been difficult to use.
We will develop Biozipcode™ as a platform with potential applications beyond diabetes, including cancer, tissue regeneration, gene therapy, and diagnostics.
Identifying Diabetes Stem Cells and Their Potential
Developing Targeted Drug Delivery Systems (Biozipcode™)
OUR VALUES
Five Values That Guide Us
Objectivity in Science
Scientific Integrity
We do not present research findings based on hope or expectation alone.
We clearly distinguish basic, preclinical, and clinical research, evaluate the data accurately, and say plainly what remains unknown.
Scientific reproducibility and transparency are essential to bringing new medical technologies into real-world use.
Root-Cause Innovation
Addressing Disease at Its Root
Our research begins by asking why a disease persists, alongside the need to manage its symptoms.
By studying diabetes stem cells and other cells associated with disease, we aim to intervene in mechanisms closer to its underlying causes.
Cell-Targeted Medicine
Biozipcode™
We study the cells involved in disease as therapeutic targets, alongside molecular targets.
Through Biozipcode™, we aim to develop technologies that identify target cells and deliver the treatments they need.
Translation
From Research to Real-World Use
Research can have its greatest impact when its benefits reach patients.
We work to translate publications, patents, technologies, and data into diagnostics, therapeutics, medical materials, licenses, and co-development programs, advancing research and business development together.
Collaboration
Better Medicine Takes Collaboration
Drug development requires a wide range of expertise.
We collaborate with people and organizations across medicine, life sciences, information science, manufacturing, regulatory affairs, clinical development, intellectual property, and business development to bring new treatments closer to patients.
FROM UNIVERSITY RESEARCH TO MEDICINE
From University Research to Global Healthcare.
Biozipcode, Inc. builds its R&D on joint research with universities.
In April 2022, the Department of Regenerative Medicine was established as a joint research department at Shiga University of Medical Science, advancing research through industry–academia collaboration. Since 2026, we have collaborated with the Department of Biocommunication Development at Kyoto University’s Graduate School of Medicine and Faculty of Medicine to further develop cell-targeted therapies.
Universities drive basic research, while companies develop intellectual property, products, clinical programs, and routes to market.
By connecting these roles, we aim to shorten the path from discovery to new medical options.
From Science to Better Care.
To bring research into real-world use, we work with pharmaceutical companies, research institutions, healthcare providers, businesses, investors, and supporters in Japan and abroad.
About Us
Grounded in diabetes stem cell research and Biozipcode™ cell-targeting technology, we work toward treatments that address the roots of hard-to-treat diseases and new approaches to care.
We work with pharmaceutical companies, research organizations, healthcare providers, and investors to advance new treatments through collaborative research, out-licensing, and co-development.
We work to take discoveries made at universities beyond the lab and develop them into diagnostic and therapeutic technologies that reach patients.
A research-driven biotech company built on joint research with universities, translating scientific findings into new diagnostic and therapeutic technologies for real-world use.
Our team brings together expertise in medicine, life sciences, information science, and business development to advance projects from basic research toward real-world applications.
Find the locations of Biozipcode, Inc. and our collaborative research sites. Please check the access information for each site before visiting.
